People · Operator
Named in public records as an officer, director or promoter · active 2022–2024 · Biotechnology, Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| RayzeBio, Inc. | — | Biotechnology | Series D+ | $396.4M | $3.4B | 2022 |
| Candid Therapeutics, Inc. | — | Pharma | Series D+ | $206.2M | $2.1B | 2024 |
Arvind Kush at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Arvind Kush on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jerel Davis | 1 | 13 |
| Aaron Royston | 1 | 7 |
| Maha Katabi | 1 | 6 |
| Aaron Kantoff | 1 | 6 |
| Kenneth Song, M.D. | 1 | 3 |
| Mary Tagliaferri | 1 | 3 |
| Ken Song | 1 | 2 |
| Alex Rosen | 1 | 2 |
| Deborah Charych | 1 | 2 |
| Angie You | 1 | 2 |
| Bong Koh | 1 | 1 |
| Jeffrey Tong, Ph.D. | 1 | 1 |
| Timothy Lu, M.D. | 1 | 1 |
| Aaron Royston, M.D. | 1 | 1 |
| Bernie Huyghe, Ph.D. | 1 | 1 |
| Michael Rome, M.D. | 1 | 1 |
| Yi Larson | 1 | 1 |
| Aubrey Haddach | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.